ARQT

Arcutis Biotherapeutics Stock Price

24.00
0.00 (0.0%)
24.00
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
$52.04
Small Cap Pro
Monthly Subscription
for only
$49.05
DDE w/Realtime (Monthly)
Monthly Subscription
for only
$34.10
VAT not included
Company Name Stock Ticker Symbol Market Type
Arcutis Biotherapeutics Inc ARQT NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.0% 24.00 07:00:00
Close Price Low Price High Price Open Price Previous Close
24.00
Bid Price Ask Price Spread News
17.25 25.97 8.72 - -
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 24.00 USD

Arcutis Biotherapeutics Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 1.05B 43.59M 23.41M $ - $ - -1.20 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% 50.91k 5.10%

more financials information »

Arcutis Biotherapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical ARQT Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week23.6924.8722.2924.12205,5030.311.31%
1 Month25.8931.4322.2924.71301,303-1.89-7.3%
3 Months27.8131.4322.2925.23205,310-3.81-13.7%
6 Months26.1039.852722.2926.68134,052-2.10-8.05%
1 Year23.0540.8817.1026.80155,3240.954.12%
3 Years23.0540.8817.1026.80155,3240.954.12%
5 Years23.0540.8817.1026.80155,3240.954.12%

Arcutis Biotherapeutics Description

Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. The company is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's pipeline includes four novel drug candidates currently in development for a range of inflammatory dermatological conditions. The firm's lead product candidate, topical roflumilast, has the potential to revitalize the standard of care for plaque psoriasis, atopic dermatitis, scalp psoriasis, and seborrheic dermatitis.


Your Recent History
NASDAQ
ARQT
Arcutis Bi..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.